Collaborative Drug Discovery
{{Multiple issues|
{{advert|date=December 2022}}
{{primary sources|date=December 2022}}
}}
{{Use mdy dates|date=December 2022}}
{{Infobox company
| name = Collaborative Drug Discovery, Inc.
| logo = CDD-Vault-LogoFB (1).jpg
| vector_logo =
| type = Private
| genre =
| foundation = {{start date and age|2004}}
| founder =
| location_city =
| location_country =
| location = Burlingame, California, U.S.
| origins =
| area_served =
| industry = {{Hlist | Life Sciences | Informatics | ELN | Pharma Intelligence}}
| products = {{Ubl | CDD Vault | PharmaKB | CDD Public}}
| revenue =
| operating_income =
| net_income =
| parent =
| divisions =
| subsid =
| owner =
| website = {{URL|collaborativedrug.com}}
| dissolved =
| footnotes =
}}
Collaborative Drug Discovery (CDD) is a software company founded in 2004 as a spin-out of Eli Lilly by Barry Bunin, PhD. CDD utilizes a web-based database solution for managing drug discovery data, primarily through the CDD Vault product which is focused around small molecules and associated bio-assay data. In 2021, CDD launched its first commercial data offering, PharmaKB,{{Cite web |url=https://www.collaborativedrug.com/about/ |title=CDD Milestones|date=July 17, 2019 |access-date=December 9, 2022 |publisher=Collaborative Drug Discovery Inc.}}{{self-published source|date=December 2022}} formerly BioHarmony,{{Cite web |url=https://www.pharmakb.com/blog/bioharmony-is-now-pharmakb-the-pharma-knowledgebase |title=PharmaKB- Knowledgebase Update |website=www.pharmakb.com}}{{self-published source|date=December 2022}}{{Cite press release |url=https://www.prnewswire.com/in/news-releases/collaborative-drug-discovery-cdd-launches-bioharmony-836337262.html |title=CDD Launches BioHarmony |website=www.prnewswire.com |access-date=December 9, 2022}}{{self-published source|date=December 2022}} as The Pharma KnowledgeBase, which is centered around pharma company, drug, and disease information for research, business intelligence, and investors.
Products
1. CDD Vault{{Cite web |url=http://tsdr.uspto.gov/documentviewer?caseId=sn77791158&docId=ORC20101207004753#docIndex=6&page=1 |title=USPTO TSDR Case Viewer}}{{Cite web |url=https://www.collaborativedrug.com/benefits/ |title=CDD Vault Benefits |date=August 11, 2019}}{{self-published source|date=December 2022}} is a research informatics web platform by Collaborative Drug Discovery. It contains several modules for collaborative project teams to manage, analyze, and share both private & public data. It is used by biotech companies, CROs, academic labs, research hospitals, agrochemical and consumer goods companies. CDD Vault is a modern web application for chemical registration, assay data management, and SAR analysis. It is designed to be simple to use and extremely secure.
2. PharmaKB is a knowledgebase for pharma-related information. Available data spans (preclinical, clinical, financial, patents, and post-approval) information about companies, drugs, and diseases. It is designed to be used by researchers, those practicing business intelligence, and investors. PharmaKB also offers real-time updates with a subscription model instead of static reports. As a throwback to CDD Vault's slogan of "Complexity Simplified", PharmaKB uses the slogan of "Data Simplified" and promotes a data trilogy of Company, Drug, and Disease. The product is meant to expand the company's scope from working with mostly preclinical researchers to being relevant for clinical and post-approval stages of drug development, including: Pharmacovigilance or Drug Safety, Regulatory Affairs, Competitive Intelligence - also referred to as Pharma Intelligence within its industry, and Pharmacoeconomics as well as investors and publishers of medical content.
Collaborations
The capability for inter-group collaboration attracted attention from the Bill & Melinda Gates Foundation, who in 2008 awarded CDD with a two million dollar grant being used to support researchers combating tuberculosis.{{Cite web |url=http://www.gatesfoundation.org/press-releases/Pages/database-tb-new-cure-081117.aspx |title=Collaborative Drug Discovery Receives Grant to Support the Development of a Database to Accelerate Discovery of New Therapies Against Tuberculosis |access-date=August 24, 2010 |archive-url=https://web.archive.org/web/20100706161034/http://www.gatesfoundation.org/press-releases/Pages/database-tb-new-cure-081117.aspx |archive-date=July 6, 2010 |url-status=dead}}
In 2010, GlaxoSmithKline released 13,471 molecules screened for activity against malaria to the public. These molecules and their associated screening data are available via CDD Public, as well in as the National Library of Medicine's PubChem and the European Bioinformatics Institute's ChEMBL database.{{Cite press release |url=http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10046.htm |publisher=GlaxoSmithKline |date=May 19, 2010 |location=London |archive-url=https://web.archive.org/web/20100601002556/http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10046.htm|url-status=dead |title=New research identifies promising leads to follow in search for medicines to fight malaria|archive-date=June 1, 2010}} This data has served as the basis for several cheminformatics analyses.{{cite journal |last1=Ekins |first1=Sean |authorlink2=Antony John Williams |last2=John Williams |first2=Antony |year=2010 |title=When Pharmaceutical Companies Publish Large Datasets: An Abundance of riches or fool's gold? |journal=Drug Discov Today |volume=15 |issue=19–20 |pages=812–815 |pmid=20732447 |doi=10.1016/j.drudis.2010.08.010}}Ekins S and Williams AJ, Meta-analysis of molecular property patterns and filtering of public datasets of antimalarial “hits” and drugs, MedChemComm, 1: 325-330, 2010. {{doi|10.1039/C0MD00129E}}Ekins S, Kaneko T, Lipinski CA, Bradford J, Dole K, Spektor A, Gregory K, Blondeau D, Ernst S, Yang J, Goncharoff N, Hohman M and Bunin BA, Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis, Mol Biosyst, 6: 2316-2324, 2010, {{doi|10.1039/C0MB00104J}}
In February 2011 CDD began participating in the collaborative MM4TB project led by Stewart Cole{{Cite web |url=https://archiveweb.epfl.ch/cole-lab.epfl.ch/index.html |title=UPCOL – Cole Lab – Chair of Microbial Pathogenesis}} and including participants from AstraZeneca and Sanofi Aventis.{{Cite web |url=http://mm4tb.org/ |title=More Medicines for Tuberculosis |website=MM4TB |archive-url=https://web.archive.org/web/20220119091111/http://mm4tb.org/ |archive-date=January 19, 2022 |url-status=dead}}
See also
References
{{Reflist}}
External links
- [http://www.collaborativedrug.com CDD's official homepage for CDD Vault]
- [https://www.pharmakb.com PharmaKB's homepage]
- [https://www.biometadata.com CDD's official homepage for BioHarmony]
{{Authority control}}
Category:Software companies based in the San Francisco Bay Area